Will Screening Sales Drive Exact Sciences' Q3 Earnings?

Core Viewpoint - Exact Sciences (EXAS) is set to report its Q3 2024 earnings on November 5, with expectations of revenue growth driven by its cancer diagnostics products, particularly Cologuard and Oncotype DX [1][2]. Group 1: Earnings Estimates - The Zacks Consensus Estimate for Exact Sciences' Q3 2024 revenues is $717.26 million, reflecting a 14.2% increase from the previous year [2]. - The expected loss per share for Q3 2024 is 20 cents, a decline from the breakeven level reported in the same quarter last year [2]. Group 2: Revenue Segments - Exact Sciences reports revenues in two main segments: Screening and Precision Oncology [4]. - Screening revenues are anticipated to have increased year-over-year, driven by growing Cologuard orders and efforts to enhance adoption through rescreens and care gap programs [4][5]. - The Zacks Consensus Estimate for Screening revenues is$ 551.6 million, with earlier expectations set between $545 million and$ 555 million, indicating a growth of 17% at the midpoint [5]. - Precision Oncology revenues are expected to benefit from laboratory service revenues from Oncotype DX, which has seen a 10% increase in international adoption over the past year [6]. - The Zacks Consensus Estimate for Precision Oncology revenues is $166 million [6]. Group 3: Earnings Prediction Model - The current model does not predict an earnings beat for Exact Sciences, as it has an Earnings ESP of 0.00% and a Zacks Rank of 3 (Hold) [7].